Ocular Therapeutix, Inc.

NasdaqGM:OCUL Stock Report

Market Cap: US$873.6m

Ocular Therapeutix Balance Sheet Health

Financial Health criteria checks 5/6

Ocular Therapeutix has a total shareholder equity of $408.0M and total debt of $66.5M, which brings its debt-to-equity ratio to 16.3%. Its total assets and total liabilities are $538.9M and $131.0M respectively.

Key information

16.3%

Debt to equity ratio

US$66.46m

Debt

Interest coverage ration/a
CashUS$482.89m
EquityUS$407.98m
Total liabilitiesUS$130.96m
Total assetsUS$538.95m

Recent financial health updates

Recent updates

Ocular Therapeutics' Impressive Surge: A Strategic Insight

Mar 19

Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement

Feb 11

Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD

Jan 10

Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking

Jan 09
Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking

Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?

Oct 15
Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?

Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

Jun 30
Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Mar 08
Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?

Feb 11
Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be

Nov 16
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be

Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt

Sep 09
Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt

Ocular Therapeutix: Trading Ahead Of An Underappreciated Catalyst Event

Aug 15

Some Analysts Just Cut Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) Estimates

May 13
Some Analysts Just Cut Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) Estimates

Financial Position Analysis

Short Term Liabilities: OCUL's short term assets ($519.8M) exceed its short term liabilities ($24.3M).

Long Term Liabilities: OCUL's short term assets ($519.8M) exceed its long term liabilities ($106.7M).


Debt to Equity History and Analysis

Debt Level: OCUL has more cash than its total debt.

Reducing Debt: OCUL's debt to equity ratio has reduced from 186.6% to 16.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OCUL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if OCUL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.